Pilot study of fludarabine (F), cyclophosphamide (C), and amifostine (A) (FCA) in patients with chronic lymphocytic leukemia (CLL).

被引：0
|
作者：
Keating, AR [1 ]
O'Brien, SM [1 ]
Cortes, JE [1 ]
Thomas, D [1 ]
Koller, C [1 ]
Beran, M [1 ]
Kantarjian, HM [1 ]
Keating, MJ [1 ]
Giles, FJ [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1401
引用
收藏
页码：313A / 313A
页数：1
相关论文
共 50 条
  • [31] Improved survival in patients with relapsed - Refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination.
    Wierda, W
    O'Brien, S
    Faderl, S
    Ferrajoli, A
    Lerner, S
    Wang, XM
    Thomas, D
    Garcia-Manero, G
    Cortes, J
    Kantarjian, H
    Keating, M
    BLOOD, 2003, 102 (11) : 110A - 110A
  • [32] Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)
    Hallek, Michael
    Fingerle-Rowson, Guenter
    Fink, Anna-Maria
    Busch, Raymonde
    Mayer, Jiri
    Hensel, Manfred
    Hopfinger, Georg
    Hess, Georg
    von Gruenhagen, Ulrich
    Bergmann, Manuela A.
    Catalano, John
    Zinzani, Pier Luigi
    Cappio, Federico Caligaris
    Seymour, John Francis
    Berrebi, Alain
    Jaeger, Ulrich
    Cazin, Bruno
    Trneny, Marek
    Westermann, Anne
    Wendtner, Clemens-Martin
    Eichhorst, Barbara F.
    Staib, Peter
    Boettcher, Sebastian
    Ritgen, Matthias
    Stilgenbauer, Stephan
    Mendila, Myriam
    Kneba, Michael
    Doehner, Hartmut
    Fischer, Kirsten
    BLOOD, 2008, 112 (11) : 125 - 125
  • [33] A UK Cost-Effectiveness Analysis Comparing First Line Treatment with Rituximab in Combination with Fludarabine and Cyclophosphamide Versus Fludarabine and Cyclophosphamide Alone in Chronic Lymphocytic Leukemia (CLL) Patients
    Papadakis, Konstantinos
    Oscier, David
    Carr, Emma S. C.
    Lewis, Gavin
    Aultman, Rick
    BLOOD, 2008, 112 (11) : 834 - 834
  • [34] A Pilot Study of Lower Doses of Ibrutinib in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)
    Bose, Prithviraj
    Chen, Lisa
    Cruz, Nichole
    Jiang, Yongying
    Wu, Qi
    Thompson, Philip A.
    Feng, Shuju
    Kroll, Michael
    Jain, Nitin
    Wierda, William G.
    Keating, Michael J.
    Gandhi, Varsha
    BLOOD, 2017, 130
  • [35] Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
    O'Brien, SM
    Kantarjian, AM
    Cortes, J
    Beran, M
    Koller, CA
    Giles, FJ
    Lerner, S
    Keating, M
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) : 1414 - 1420
  • [36] Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia
    Schiavone, EM
    De Simone, M
    Palmieri, S
    Annunziata, M
    Pocali, B
    Copia, C
    D'Amico, MR
    Del Vecchio, L
    Ferrara, F
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (01) : 23 - 28
  • [37] Fludarabine with cyclophosphamide and mitoxantrone (FCM) in resistant or relapsed chronic lymphocytic leukemia (CLL):: Final results of a phase II study.
    Bosch, F
    Ferrer, A
    López-Guillermo, A
    Giné, E
    Cobo, F
    Perales, M
    Esteve, J
    Villamor, N
    Colomer, D
    Bellosillo, B
    Ribera, JM
    Altes, A
    Besalduch, J
    Montserrat, E
    BLOOD, 2001, 98 (11) : 634A - 634A
  • [38] Fludarabine as therapy in chronic lymphocytic leukemia (CLL) in patients over 70 years.
    Conte, GF
    Aravena, PC
    Fardella, PD
    Alfaro, JI
    Araos, DM
    Flores, CIDA
    González, NA
    BLOOD, 2002, 100 (11) : 363B - 363B
  • [39] Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL).
    Bosch, F
    Perales, M
    Cobo, F
    Esteve, J
    Rafel, M
    LopezGuillermo, A
    Ribera, JM
    Campo, E
    Montserrat, E
    BLOOD, 1997, 90 (10) : 2360 - 2360
  • [40] Clinical management of high risk chronic lymphocytic leukemia (CLL) with fludarabine, Rituxan® and cyclophosphamide (FRC) regimen.
    Shurafa, MS
    Wang, D
    VanDyke, D
    Maeda, K
    Alaman-Canoso, RT
    Janakiraman, N
    Nath, R
    Wiktor, A
    Baldy, C
    BLOOD, 2001, 98 (11) : 293B - 293B
12345